VESALIUS-CV: Evolocumab (Repatha) Achieves Primary Endpoints in Patients with ASCVD

Amgen's PCSK9 inhibitor, evolocumab (Repatha), successfully met dual primary endpoints in the Phase 3 VESALIUS-CV trial, demonstrating a statistically and clinically significant reduction in major adverse cardiovascular events (MACE) risk among patients with atherosclerotic cardiovascular disease (ASCVD) who had no prior history of heart attack or stroke. This outcome, with no new safety signals, positions Repatha to potentially expand its market reach to a primary prevention population, reinforcing its role as a cornerstone therapy in lipid management. Full trial results are anticipated at the American Heart Association Scientific Sessions on November 8, 2025.

Analysis

Amgen has announced a significant clinical victory for its PCSK9 inhibitor, evolocumab (Repatha), with the Phase 3 VESALIUS-CV trial successfully meeting its dual primary endpoints. The study, involving over 12,000 patients with established atherosclerotic cardiovascular disease (ASCVD) but no prior heart attack or stroke, demonstrated a statistically and clinically significant reduction in major adverse cardiovascular events (MACE). This outcome is pivotal as it expands Repatha's clinical profile into primary prevention for a high-risk population, positioning it as the first and only PCSK9 inhibitor with such evidence. The absence of new safety signals over a median follow-up of approximately 4.5 years is critical for physician confidence and potential adoption in this broader patient base. The announcement de-risks a key asset for Amgen and sets the stage for a substantial market expansion. Full data, expected at the American Heart Association Scientific Sessions on November 8, 2025, will be a key catalyst for quantifying the magnitude of the benefit and its commercial implications.

Key Decisions for Investors

• The positive trial results represent a significant catalyst for Amgen, supporting a bullish thesis on Repatha's long-term revenue potential through expansion into the primary prevention market.
• Investors should closely monitor the full data presentation on November 8, 2025, as the specific magnitude of MACE reduction will be critical for updating peak sales forecasts and assessing the drug's competitive positioning.
• This development strengthens Repatha's market-leading status, creating a competitive moat that could accelerate market share capture from other lipid-lowering therapies and rival PCSK9 inhibitors lacking primary prevention data.